• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tempest Therapeutics, Inc. - Common Stock (NQ:TPST)

1.905 -0.035 (-1.80%)
Streaming Delayed Price Updated: 2:05 PM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Tempest Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
These stocks are moving in today's session ↗
March 23, 2026
Via Chartmill
Wednesday's pre-market session: top gainers and losers ↗
February 18, 2026
Via Chartmill
The market is filled with gapping stocks in Thursday's session. ↗
January 22, 2026
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
November 20, 2025
 
Via Benzinga
News headline image
Tempest Therapeutics Stock Plummets Nearly 50% Amid Shareholder Dilution Fears Following CAR-T Acquisition
November 19, 2025
San Francisco, CA – November 19, 2025 – Tempest Therapeutics, Inc. (NASDAQ: TPST) saw its stock price plummet by a staggering 48.92% today, wiping out nearly half of its market value in a single... 
Via MarketMinute
News headline image
TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction ↗
November 19, 2025
The transaction is expected to close in early 2026, provided it receives all required approvals. 
Via Stocktwits
News headline image
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results ↗
November 19, 2025
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
November 19, 2025
 
Via Benzinga
News headline image
Nasdaq Gains Over 100 Points; Target Trims Earnings Forecast ↗
November 19, 2025
 
Via Benzinga
News headline image
Why Tempest Therapeutics (TPST) Stock Is Down 45% Today ↗
November 19, 2025
Tempest Therapeutics shares fell Wednesday after the announcement of an all-stock acquisition of dual-CAR T programs from Factor Bioscience. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
October 17, 2025
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
September 04, 2025
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
June 11, 2025
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
June 09, 2025
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs. 
Via Chartmill
News headline image
Why Circle Internet Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗
June 09, 2025
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Monday's pre-market session. ↗
June 09, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
June 09, 2025
 
Via Benzinga
News headline image
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success ↗
April 10, 2025
Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program. 
Via Benzinga
News headline image
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger ↗
April 10, 2025
CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat in advanced liver cancer and FDA clearance for a pivotal Phase 3 study. 
Via Stocktwits
Topics World Trade
News headline image
Monday's session: gap up and gap down stocks ↗
April 07, 2025
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Tuesday's after hours session: top gainers and losers ↗
March 04, 2025
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
October 30, 2024
 
Via Benzinga
News headline image
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗
October 30, 2024
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
October 16, 2024
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
October 10, 2024
 
Via Benzinga
News headline image
Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday? ↗
October 10, 2024
Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
October 10, 2024
 
Via Benzinga
News headline image
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday? ↗
August 15, 2024
Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin... 
Via Benzinga
News headline image
TPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024 ↗
August 09, 2024
TPST stock results show that Tempest Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
$55M Bet On Archer Aviation? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying ↗
July 05, 2024
 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap